Elan's nicotine patch
Executive Summary
Warner-Lambert will market the smoking cessation product worldwide under an agreement announced Dec. 2. When approved, the patch will be marketed in the U.S. by the company's newly created cardiovascular sales force, which also has responsibility for Lopid. IMS data notes that sales of smoking cessation products in the U.S. will reach nearly $80 mil. in 1988, up from $58 mil. in 1987, with 10% increases expected over the next several years. IMS estimates the worldwide market at about $100 mil.....
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.